Dr Reddy's unveils generic version of Lyrica capsules in US for treating neuropathic pain
Dr Reddy's Labs' Pregabalin capsule is a generic version of C P Pharmaceuticals International C V's Lyrica capsules which had US sales of around $5,462 million for the twelve months ended May 2019.
New Delhi: Dr Reddy's Laboratories on July 30 said it has launched Pregabalin capsules, used to treat neuropathic pain, in the US market.
The company has launched the product after getting approval from the US Food and Drug Administration (USFDA), Dr Reddy's Labs said in a statement.
The product is a generic version of C P Pharmaceuticals International C V's Lyrica capsules which had US sales of around $5,462 million for the twelve months ended May 2019.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd